Chimeric Therapeutics granted FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Posted: 8 December 2025 Chimeric Therapeutics Ltd has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for CHM CDH17 in the treatment of gastric cancer. The designation is recognised as a significant milestone…
Cartherics launches spin-out Evinco to advance immune-based therapies for Alzheimer’s disease
Posted: 8 December 2025 Evinco Therapeutics Pty Ltd has been officially launched in Melbourne as a new biotechnology company dedicated to transforming treatments for Alzheimer’s disease and other neuroinflammatory conditions. Based in Melbourne and led by CEO and…
Thermo Fisher Scientific expands Bioprocess Design Centers to strengthen Asia’s biopharma manufacturing capacity
Posted: 5 December 2025 Thermo Fisher Scientific announces a significant expansion of its Bioprocess Design Centers across Asia, deepening its investment in the region’s rapidly advancing biopharmaceutical sector. The company is opening a new centre in Hyderabad, India,…
New MTPConnect report highlights strong commercial and clinical outcomes from its CTCM Medtech program
Posted: 5 December 2025 A new report has been released detailing the strong outcomes achieved through MTPConnect’s Clinical Translation Commercialisation Medtech (CTCM) Programme, highlighting the advances made by emerging Australian medtech companies supported through the initiative. Speaking at…
CSL Seqirus opens world-class $1bn vaccine and antivenom manufacturing facility in Melbourne
Posted: 5 December 2025 Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL Seqirus’ state-of-the-art cell-based influenza vaccine and antivenom manufacturing facility in…
Florey Institute study reveals neural activity directly drives faster glioma growth
Posted: 1 December 2025 A new study led by The Florey has revealed that heightened neural excitability in the brain directly drives increased growth of glioma, an aggressive and currently incurable form of brain cancer. “Glioma is a…
Akesa unveils new Aksys digital platform to streamline access to private-script medicines in hospitals
Posted: 1 December 2025 Akesa has launched the Aksys platform as a digital solution designed to simplify how Australian hospitals access non-Pharmaceutical Benefits Scheme (PBS) reimbursed prescription medicines. The platform is positioned as a major advancement in improving…
4DMedical celebrated as a high-growth Australian innovator, ranking seventh in Deloitte’s Tech Fast 50
Posted: 1 December 2025 4DMedical has been ranked seventh in the Deloitte 2025 Tech Fast 50 after recording a 715% increase in revenue across the past three years. The ranking is a recognition of the organisation’s rapid expansion…
Cartherics announces appointment of Dr Ian Nisbet as Chief Executive Officer
Posted: 28 November 2025 Cartherics Pty Ltd has announced that Dr Ian Nisbet has been appointed Chief Executive Officer as part of a planned leadership transition designed to support the company’s next phase of growth. The announcement followed…
Planet Innovation secures role in USD$25.1 million consortium advancing rapid mNGS respiratory diagnostic
Posted: 28 November 2025 Planet Innovation (PI) has been selected as a core technology partner in a USD$25.1 million international consortium formed to develop a rapid, point-of-care sequencing test for respiratory pathogens. Led by Ginkgo Bioworks, the group…
Amplia Therapeutics receives positive FDA feedback regarding planned Phase 2b/3 pancreatic cancer trial
Posted: 28 November 2025 Amplia Therapeutics Limited announced that positive feedback had been received from the United States Food and Drug Administration (FDA) following a recent Type D meeting, providing support for the company’s planned late-stage clinical trial…
WEHI’s new $8 Million PURPLE translational platform to accelerate new approaches to pancreatic cancer treatment
Posted: 28 November 2025 WEHI’s new groundbreaking digital platform uniting patients, clinicians and researchers was unveiled as a major step toward transforming pancreatic cancer care, supported through an $8 million philanthropic commitment from The Hemstritch Centre of Excellence…
